{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:02:27Z","timestamp":1762506147379,"version":"build-2065373602"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T00:00:00Z","timestamp":1372896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,8]]},"abstract":"\n Objective<\/jats:title>\n \n \n \n \n To assess the efficacy of fesoterodine 8\u2009mg vs extended\u2010release (\n ER<\/jats:styled-content>\n ) tolterodine 4\u2009mg for overactive bladder (\n OAB<\/jats:styled-content>\n ) symptoms in terms of patient\u2010reported outcomes in women and in men.\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Subjects and Methods<\/jats:title>\n \n \n \n Pooled data from two 12\u2010week, randomized, double\u2010blind, double\u2010dummy studies were analysed.<\/jats:p>\n <\/jats:list-item>\n \n \n Participants eligible for the studies were \u226518 years old, had self\u2010reported\n OAB<\/jats:styled-content>\n symptoms for \u22653 months in 3\u2010day baseline diaries and had \u22658 micturitions and \u22651 urgency urinary incontinence (\n UUI<\/jats:styled-content>\n ) episode per 24\u2009h.\n <\/jats:p>\n <\/jats:list-item>\n \n \n Individuals were randomized to fesoterodine (4\u2009mg for 1 week then 8\u2009mg for 11 weeks),\n ER<\/jats:styled-content>\n tolterodine (4\u2009mg), or placebo.\n <\/jats:p>\n <\/jats:list-item>\n \n \n Changes from baseline in 3\u2010day bladder diary variables and scores from the\n P<\/jats:styled-content>\n atient\n P<\/jats:styled-content>\n erception of\n B<\/jats:styled-content>\n ladder\n C<\/jats:styled-content>\n ondition (\n PPBC<\/jats:styled-content>\n ),\n U<\/jats:styled-content>\n rgency\n P<\/jats:styled-content>\n erception\n S<\/jats:styled-content>\n cale (\n UPS<\/jats:styled-content>\n ), and\n O<\/jats:styled-content>\n veractive\n B<\/jats:styled-content>\n ladder\n Q<\/jats:styled-content>\n uestionnaire (\n OAB<\/jats:styled-content>\n \u2010q), were assessed, as was the \u2018diary\u2010dry\u2019 rate (the proportion of subjects with >0\u2009\n UUI<\/jats:styled-content>\n episodes according to baseline diary and no\n UUI<\/jats:styled-content>\n episodes according to post\u2010baseline diary).\n <\/jats:p>\n <\/jats:list-item>\n \n The primary endpoint was the change from baseline to week 12 in UUI episodes.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n \n \n \n At week 12, women showed significantly greater improvement with fesoterodine 8\u2009mg (\n n<\/jats:italic>\n = 1374) than with\n ER<\/jats:styled-content>\n tolterodine 4\u2009mg (\n n<\/jats:italic>\n = 1382) and placebo (\n n<\/jats:italic>\n = 679) in\n UUI<\/jats:styled-content>\n episodes (primary endpoint), micturition frequency, urgency episodes, and all other diary endpoints (except nocturnal micturitions versus ER tolterodine), and also in scores on the\n PPBC<\/jats:styled-content>\n ,\n UPS<\/jats:styled-content>\n , and all\n OAB<\/jats:styled-content>\n \u2010q scales and domains (all\n P<\/jats:italic>\n < 0.005).\n <\/jats:p>\n <\/jats:list-item>\n \n \n Diary\u2010dry rates in women were significantly greater with fesoterodine (63%) than with tolterodine (57%;\n P<\/jats:italic>\n = 0.002) or placebo (48%;\n P<\/jats:italic>\n < 0.0001).\n <\/jats:p>\n <\/jats:list-item>\n \n \n In men, there were no significant differences in improvement in\n UUI<\/jats:styled-content>\n episodes between any treatment groups at week 12. Improvements in men were significantly greater with fesoterodine 8\u2009mg (\n n<\/jats:italic>\n = 265) than with\n ER<\/jats:styled-content>\n tolterodine (\n n<\/jats:italic>\n = 275) for severe urgency and the\n OAB<\/jats:styled-content>\n \u2010q Symptom Bother domain and were also significantly greater with fesoterodine than with placebo (\n n<\/jats:italic>\n = 133) for micturition frequency, urgency episodes, severe urgency episodes,\n PPBC<\/jats:styled-content>\n responses and scores on all\n OAB<\/jats:styled-content>\n \u2010q scales and domains at week 12 (all\n P<\/jats:italic>\n < 0.04).\n <\/jats:p>\n <\/jats:list-item>\n \n \n The most frequently reported treatment\u2010emergent adverse events in both genders were dry mouth (women: fesoterodine, 29%;\n ER<\/jats:styled-content>\n tolterodine, 15%; placebo, 6%; men: fesoterodine, 21%;\n ER<\/jats:styled-content>\n tolterodine, 13%; placebo, 5%) and constipation (women: fesoterodine, 5%;\n ER<\/jats:styled-content>\n tolterodine, 4%; placebo, 2%; men: fesoterodine, 5%;\n ER<\/jats:styled-content>\n tolterodine, 3%; placebo, 1%).\n <\/jats:p>\n <\/jats:list-item>\n \n \n Urinary retention rates were low in women (fesoterodine, <1%;\n ER<\/jats:styled-content>\n tolterodine, <1%; placebo, 0%) and men (fesoterodine, 2%;\n ER<\/jats:styled-content>\n tolterodine <1%; placebo, 2%).\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n \n \n \n This analysis supports the superiority of fesoterodine 8\u2009mg over\n ER<\/jats:styled-content>\n tolterodine 4\u2009mg on diary endpoints, including\n UUI<\/jats:styled-content>\n , symptom bother and health\u2010related quality of life in women.\n <\/jats:p>\n <\/jats:list-item>\n \n \n In men, fesoterodine 8\u2009mg was superior to\n ER<\/jats:styled-content>\n tolterodine 4\u2009mg for improving severe urgency and symptom bother.\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/bju.12174","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T09:59:03Z","timestamp":1372931943000},"page":"373-385","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Efficacy of fesoterodine compared with extended\u2010release tolterodine in men and women with overactive bladder"],"prefix":"10.1111","volume":"112","author":[{"given":"David","family":"Ginsberg","sequence":"first","affiliation":[{"name":"Department of Urology University of Southern California Los Angeles CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Schneider","sequence":"additional","affiliation":[{"name":"Praxisklinik Urologie Rhein\/Ruhr M\u00fclheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Con","family":"Kelleher","sequence":"additional","affiliation":[{"name":"St. Thomas' Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Van Kerrebroeck","sequence":"additional","affiliation":[{"name":"Department of Urology Maastricht University Medical Center Maastricht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Swift","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Medical University of South Carolina Charleston SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Creanga","sequence":"additional","affiliation":[{"name":"Consultant to Pfizer Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane L.","family":"Martire","sequence":"additional","affiliation":[{"name":"Pfizer Inc New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,7,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0b013e32832ce8a4"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01113-4"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-004-0455-3"},{"issue":"19","key":"e_1_2_7_5_1","first-page":"S608","article-title":"Health\u2010related quality of life of patients receiving extended\u2010release tolterodine for overactive bladder","volume":"8","author":"Kelleher CJ","year":"2002","journal-title":"Am J Manag Care"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP47384"},{"key":"e_1_2_7_7_1","first-page":"13","article-title":"The mechanism of action of tolterodine","volume":"11","author":"Nilvebrant L","year":"2000","journal-title":"Rev Contemp Pharmacother"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.41.1.815"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-003-0832-2"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.10.1787"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986709789712835"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP46556"},{"volume-title":"Full Prescribing Information","year":"2011","author":"Toviaz\u00ae (fesoterodine fumarate)","key":"e_1_2_7_13_1"},{"key":"e_1_2_7_14_1","unstructured":"European Medicines Agency.EPARs for authorized medicinal products for human use. European Public Assessment Report for Toviaz (Product Information).2012. Available at:http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000723\/human_med_001099.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d125. Accessed May 14 2013"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.07.009"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.033"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07710.x"},{"volume-title":"Initial National Priorities for Comparative Effectiveness Research","year":"2009","author":"Prioritization CoCER","key":"e_1_2_7_18_1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09086.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09640.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.01.007"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05345.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016370925601"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.03.088"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07907.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-009-0857-2"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.09.007"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.09.018"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04463.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.01.027"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05889.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000149947.28100.cd"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-007-0420-y"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20545"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.047"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02035.x"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21099"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09587.x"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.12174","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.12174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:15:28Z","timestamp":1761754528000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.12174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,4]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/bju.12174"],"URL":"https:\/\/doi.org\/10.1111\/bju.12174","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2013,7,4]]},"assertion":[{"value":"2013-07-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}